The Cholangiocarcinoma Conference: Molecular Drivers, Microenvironment, and Precision Medicine

胆管癌会议：分子驱动因素、微环境和精准医学

• 批准号: 10747566
• 负责人: ALPHONSE E SIRICA
• 金额: $ 1.4万
• 依托单位: FEDERATION OF AMER SOC FOR EXPER BIOLOGY
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2024-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10747566
• 关键词: Address; Adenocarcinoma; Advocate; Affect; Area; Award; Basic Science; Biological; Cholangiocarcinoma; Classification; Clinical; Clinical Management; Clinical Research; Clinical Trials; Collaborations; Colorectal Cancer; Communities; Complex; Country; Curative Surgery; Detection; Development; Diabetes Mellitus; Diagnosis; Discipline; Disease Progression; Educational workshop; Epithelium; Excision; Genomics; Goals; Hepatobiliary; Heterogeneity; Human; Immune; Immunologic Surveillance; Incidence; International; Intrahepatic Cholangiocarcinoma; Knowledge; Link; Liver parenchyma; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Mentors; Molecular; Monitor; Obesity; Oral; Pancreatic Ductal Adenocarcinoma; Pathogenesis; Patient advocacy; Patients; Persons; Pharmaceutical Preparations; Pre-Clinical Model; Prevention; Primary Malignant Neoplasm of Liver; Primary carcinoma of the liver cells; Prognosis; Research; Research Personnel; Risk Factors; Role; Scientist; Survival Rate; Talents; Translational Research; Unresectable; Viral hepatitis; advanced disease; advocacy organizations; biliary tract; biomarker signature; career; career development; collaborative environment; drug discovery; epigenomics; human model; improved; innovation; insight; interest; meetings; microbiome; mortality; multiple omics; new technology; novel; novel strategies; personalized approach; personalized immunotherapy; personalized medicine; posters; precision medicine; recruit; survival outcome; symposium; targeted agent; targeted treatment; therapeutic target; therapy resistant; trend; tumor; tumor heterogeneity; tumor microenvironment

Project Summary/Abstract Cholangiocarcinoma (CCA) is a macro-molecularly diverse hepato-biliary tract malignancy that accounts for approximately 3.0% of gastrointestinal malignancies and between 10% to 20% of primary liver cancers. Over the past 10-20 years, CCA has become the focus of heightened interest and concern, due in large part to the now well recognized increasing incidence of intrahepatic CCA in various countries around the world, as well as with CCA’s globally high mortality rates also rising in several areas of the world, including the USA. Most CCA patients are diagnosed with advanced disease, where treatment options are limited and overall, 5-year survival rates are dismal. However recent advances in a growing number of targeted therapies and clinical trials are offering some hope for improving survival outcomes for advanced CCA patients. To our knowledge, this FASEB Scientific Conference represents the first-of-its kind 4- day in person comprehensive scientific meeting solely devoted to CCA. It brings together a diverse group of senior and talented early career investigators to critically assess important areas of current and evolving basic, translational, and clinical research focused on addressing the major challenges that continue to limit progress towards achieving significant improvements in CCA prevention, clinical management, and patient survival outcomes. Key topic areas that will be addressed include (1) the challenges of inter- and intra-tumoral heterogeneity, (2) the roles of the microbiome and tumor microenvironment in affecting disease progression, therapeutic resistance, and immunosurveillance, (3) cellular origins, lineage, and genomic relationships between CCA and hepatocellular carcinoma, (4) identification of novel and more effective biomarker signatures for early CCA detection and for monitoring prognosis and treatments; (5) advances in “multi-omics” for personalizing therapies, (6) innovative preclinical modeling for CCA drug discovery, (7) current and emerging trends in CCA personalized medicine, and (8) exploring new technologies and approaches for CCA therapies. Additional important aims of this much needed conference involve providing a collegial and collaborative environment that supports early career investigator development, promotes scientific cross-talk between different scientific and clinical disciplines, mentors underrepresented researchers actively engaged or interested in joining the CCA research community, and encourages networking with international CCA research consortiums and patient advocacy organizations. The ultimate aim is to advance new and effective strategies for greatly reducing the human impact of this highly fatal malignancy.

项目摘要/摘要 胆管细胞癌(CCA)是一种大分子多样化的肝胆道恶性肿瘤。 约占胃肠道恶性肿瘤的3.0%，10%至20% 原发性肝癌。在过去的一二十年里，CCA已经成为高度关注的焦点 兴趣和关切，这在很大程度上是由于现在公认的 肝内CCA在世界各国以及与CCA的全球最高 包括美国在内的世界多个地区的死亡率也在上升。大多数CCA患者 被诊断为晚期疾病，治疗选择有限，总体来说，为期5年 存活率令人沮丧。然而，越来越多的靶向治疗的最新进展 临床试验为改善晚期CCA的生存结果提供了一些希望。 病人。据我们所知，这次FASE B科学会议是同类会议中的第一次。 专门讨论CCA的一天面对面的综合科学会议。它汇集了一个 由不同的资深和有才华的早期职业调查人员组成的小组，对重要的 当前和不断发展的基础、翻译和临床研究领域，侧重于解决 继续限制取得重大改善进展的主要挑战 在CCA预防、临床管理和患者生存结果方面。关键主题领域 将解决的问题包括(1)瘤内和瘤内异质性的挑战，(2) 微生物组和肿瘤微环境在影响疾病进展中的作用 治疗耐药性和免疫监测，(3)细胞来源、谱系和基因组 CCA与肝细胞癌的关系(4)新的和更多的发现 用于早期CCA检测和监测预后的有效生物标志物标志 治疗；(5)个性化治疗的“多组学”进展；(6)创新的临床前 CCA药物发现的建模，(7)CCA个性化的当前和新兴趋势 医学，以及(8)探索CCA疗法的新技术和方法。其他内容 这次迫切需要的会议的重要目标包括提供一个合议性和协作性的 支持早期职业调查员发展的环境，促进科学相声 在不同的科学和临床学科之间，导师对研究人员的代表性不足 积极参与或有兴趣加入共同国家评估研究社区，并鼓励 与国际CCA研究联盟和患者倡导组织建立联系。 最终目标是提出新的有效战略，大幅减少人类 这种高度致命的恶性肿瘤的影响。